Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
Real-time Quote. Real-time Tradegate - 08/17 03:30:44 pm
108.426 EUR   +0.30%
08/16 Seven charged in U.S. insider trading ring
08/16 RESEARCH COLLAB : -- Bayer and the Citrus Research and Development F..
08/16DJBayer Joins Fight Against Citrus Greening Disease
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Bayer Stops Sale of Glucose Meter Business

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/09/2013 | 12:07pm CEST

By Hendrik Varnholt

FRANKFURT--German pharmaceutical company Bayer AG (>> Bayer AG) will retain its blood glucose meter business, a spokeswoman said Wednesday, confirming a Bloomberg report.

Bayer had put up the unit for sale and had been in talks with French peer Sanofi SA (>> SANOFI) about a deal which could have been valued at around $1.5 billion, people familiar with the matter told Dow Jones Newswires in December.

"We have evaluated several options and decided to retain it," Bayer HealthCare chief Joerg Reinhardt said about the glucose meter business, according to Bloomberg.

Natali Schwab, Eyk Henning and Dana Cimilluca contributed to this story.

Write to Hendrik Varnholt at hendrik.varnholt@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bayer AG, SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
02:12p BAYER : Modification/Amendment - Preventive Maintenance Repair services for two ..
02:06p BAYER : Presolicitation Notice - J-- Preventive Maintenance Repair services for ..
08/16 Seven charged in U.S. insider trading ring
08/16 RESEARCH COLLABORATION TO FIGHT DEVA : -- Bayer and the Citrus Research and Deve..
08/16DJBayer Joins Fight Against Citrus Greening Disease
08/14 BAYER : Sources Sought - Maintenance & repair of Medrad stellant injectors
08/14 BAYER : Sources Sought Notice - J-- Maintenance & repair of Medrad stellant inje..
08/11 BAYER : and SICIT 2000 sign exclusive distribution agreement
08/08 BAYER : Sources Sought - 506-18-1-1527-0016 - Medrad Service Contract Preventive..
08/08 BAYER : Sources Sought Notice - J-- 506-18-1-1527-0016 - Medrad Service Contract..
More news
News from SeekingAlpha
08/16 Biogen's Alzheimer's Hope Tops The Sector's Most Valuable Pipeline Projects
08/16 Tracking David Einhorn's Portfolio - Q2 2017 Update
08/15 Global Oligopolies - Investing In Concentrated Businesses
08/15 PROGENICS : Dynavax 2.0?
08/15 Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q2 2017 Update
Financials (€)
Sales 2017 49 579 M
EBIT 2017 9 424 M
Net income 2017 5 544 M
Debt 2017 11 252 M
Yield 2017 2,59%
P/E ratio 2017 17,16
P/E ratio 2018 15,62
EV / Sales 2017 2,03x
EV / Sales 2018 1,94x
Capitalization 89 393 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 120 €
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER9.05%105 305
JOHNSON & JOHNSON15.77%360 112
NOVARTIS10.12%220 515
ROCHE HOLDING LTD.5.33%218 264
PFIZER2.71%198 663
MERCK AND COMPANY6.51%171 005